PressSeptember 18, 2024 Awakn Life Sciences Announces Upsizing and Closing of Tranche of Private Placement Financing
PressSeptember 18, 2024 Psyence Group’s NASDAQ-Listed Associate, Psyence Biomed Issues Shareholder Update Recapping Recent Progress and Previewing Key Upcoming Data Milestones
PressSeptember 18, 2024 Revive Therapeutics Announces Strategic Focus on Bucillamine for Infectious Diseases and Medical Countermeasures
PressSeptember 16, 2024 Psyence Biomed Issues Shareholder Update Recapping Recent Progress and Previewing Key Upcoming Data Milestones
PressSeptember 16, 2024 Psyence Biomedical Ltd. Announces Receipt of Staff Delisting Determination from Nasdaq
PressSeptember 12, 2024 Psyence Biomed Announces the Signing of a Conditional Binding Term Sheet for the Acquisition of Psilocybin-Based Drug Developer Clairvoyant
PressSeptember 12, 2024 Psyence Biomed Announces Initiation of First Trial Site in Australia for its Phase IIb Study of Nature Derived Psilocybin as a Potential Treatment for Adjustment Disorder in Palliative Care
PressSeptember 12, 2024 Revitalist Announces Strategic Partnership with Sama Therapeutics to Advance Digital Human AI Agents for Precision Mental Health
PressSeptember 12, 2024 Clearmind Medicine Announces Publication of International Patent Application for Innovative MDMA-Based Combination Treatment
PressSeptember 12, 2024 Bright Minds Biosciences Initiates the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy
PressSeptember 12, 2024 Clearmind Medicine and Yissum File International Patent Application for Revolutionary Psychedelic Compounds for PTSD Treatment
PressSeptember 10, 2024 Silo Pharma Announces Completion of FDA Pre-IND Meeting to Advance Development of SPC-15 for Treatment of PTSD
PressSeptember 10, 2024 Incannex Healthcare Announces Strategic Financing for up to $60 Million with Arena Investors
PressSeptember 5, 2024 Revitalist Lifestyle and Wellness Ltd. Partners with Wake Network to Launch Lion’s Brain Supplements for Enhanced Mental Clarity and Wellbeing
PressSeptember 4, 2024 atai Life Sciences to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
PressSeptember 4, 2024 Psyence Biomed Announces Worldwide Exclusive Licensing Agreement with PsyLabs to Supply Nature-Derived Psilocybin to be Evaluated as a Potential Treatment for Alcohol Use Disorder (AUD) and Other Substance Use Disorders (SUDs)
PressSeptember 4, 2024 Cybin to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
PressSeptember 3, 2024 Red Light Holland Launches FarmCare Health to Revolutionize Healthcare with Farm-Fresh Food Prescriptions
PressAugust 30, 2024 SciSparc-Clearmind Medicine Collaboration Leads to Publication of Application for Innovative Ketamine-Based Combination
PressAugust 30, 2024 Clearmind Medicine Announces Publication of its Patent Application for Innovative Ketamine-Based Combination Treatment
PressAugust 30, 2024 Psyence Biomed Announces Registration Statement on Form F-1 for Up to $25 Million Equity Line of Credit with White Lion Capital, LLC, Declared Effective by SEC
